Search Results
A Source of Hope: Understanding Bone Marrow and Stem Cell Transplants
Imagine a community filled with families, friends, and healthcare professionals united to transform the meaning of living with blood cancer. This diverse group of people—including researchers, doctors, care partners, and healthcare teams—are bound together by hope, resilience, and a shared goal: to overcome the challenges and live longer better lives.
Bold goal, bold action
As we observe World Cancer Day, I’m reflecting on my own family’s experience with blood cancer, the children with blood cancer I have had the honor of knowing, and the many individuals and families who have been impacted by a blood cancer diagnosis.
Our work at The Leukemia & Lymphoma Society (LLS) has had a positive impact on so many, but we can do even more to accelerate progress for the blood cancer patients we serve.
CAR T-cell therapy in central nervous system (CNS) lymphoma: a study in safety and efficacy and a model in which to study mechanisms of neurotoxicity
CAR T-cells are highly effective in lymphoma but limited by a profound and potentially fatal toxicity involving the central nervous system (CNS). Little is known about how CAR T-cells eliminate lymphoma cells in the CNS nor how this therapy causes toxicity. I will study CAR T-cells in patients with CNS lymphomas with the goal of expanding CAR T-cell indications. I will also examine serial blood and CNS samples to understand neurologic toxicity to inform new therapies to control this toxicity.Bleomycin
Bleomycin is FDA approved as a single agent or in proven combinations to treat people who have Hodgkin and non-Hodgkin lymphoma. Bleomycin may cause a temporary loss of hair in some people. Normal hair growth should return after treatment ends (although it may take several months).
Copanlisib
Copanlisib is FDA approved for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Moms In Training: Keeping on Track
Staying on track while you train for a walk or run event can be challenging at times. This is especially true for busy moms who barely have enough time to work out, let alone track their fitness progress.
One Family’s Inspiring Quest to Help Other Families Impacted By Cancer
A nasty cough and extreme fatigue first led Myrna and Lou Binder to bring their 12-year-old son, Jeff, to the doctor for an examination. But the flu-like symptoms persisted until more tests enabled the doctors to arrive at the shocking diagnosis: non-Hodgkin lymphoma. The year was 1975.
Plerixafor
Plerixafor injection is FDA approved for use along with a granulocyte colony-stimulating factor (G-CSF) medication in preparation for an autologous stem cell transplant in patients with non-Hodgkin lymphoma or myeloma. Plerixafor injection works by causing certain blood cells to move from the bone marrow to the blood so that they can be removed for transplantation.
Rasburicase
Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.
A College Freshmen Faces A Cancer Diagnosis
The symptoms I habitually pushed off as stressors from my first semester of college, began to accumulate. Throughout the semester I felt less like my healthy self because of coughing, abnormal skin reactions, unexplainable fatigue and diminishing motivation.
Lomustine
Lomustine is FDA approved as a secondary therapy in combination with other drugs to treat people with Hodgkin lymphoma who relapse while being treated with primary therapy or who fail to respond to primary therapy.
Nelarabine
Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.
Nivolumab
Nivolumab is FDA approved for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.